34 results
8-K
EX-4.1
GLUE
Monte Rosa Therapeutics Inc
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy
8-K
EX-10.1
GLUE
Monte Rosa Therapeutics Inc
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
.
3.1. Upon the satisfaction of the conditions set forth in Section 6, the completion of the purchase and sale of the Placement Securities (the “Closing … of a material right or of a material debt owed to it;
(v) any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
to the satisfaction of customary closing conditions.
The gross proceeds to Monte Rosa from this offering are expected to be approximately $25 million
424B5
mq4 pwph9dv1dg0fq
26 Oct 23
Prospectus supplement for primary offering
4:55pm
S-3
cnmvj5
1 Jul 22
Shelf registration
5:01pm
S-3
EX-4.5
aw587hfzx 5u8sxv05
1 Jul 22
Shelf registration
5:01pm
S-3
EX-1.2
5ttz7 lyv4c5
1 Jul 22
Shelf registration
5:01pm
S-3
EX-4.6
dwqo0
1 Jul 22
Shelf registration
5:01pm
10-K
pw6g7uc7it3la6tbs
29 Mar 22
Annual report
4:15pm
10-K
EX-10.20
qkpx9ayuu5npae8fu
29 Mar 22
Annual report
4:15pm
10-Q
wmgm7olpg
12 Aug 21
Quarterly report
4:22pm
S-8
EX-99.2
0bqqw
25 Jun 21
Registration of securities for employees
4:03pm
424B4
7nrd3
25 Jun 21
Prospectus supplement with pricing info
6:08am
S-1/A
csuao06
9 Jun 21
IPO registration (amended)
4:51pm